Pomalidomide on alternate days in patients with refractory multiple myeloma

SAKK 39/16 OptiPOM

Coordinating investigator

Dr. med.
Luzerner Kantonsspital
+41 41 205 11 11

Trial SAKK 39/16 OptiPOM will be investigating ways of improving the treatment of advanced multiple myeloma. Multiple myeloma is a malignant disease of a specific group of blood cells called plasma cells and can severely damage bones, kidneys and haematopoiesis.

The focal trial medication is pomalidomide (Imnovid®), an immunomodulator used to treat multiple myeloma. The aim of the study is to test the tolerability and efficacy of pomalidomide when taken every two days instead of daily, as is normal practice at the moment. There are already good indications that the medicine is better tolerated if taken according to this regimen (fewer changes in blood count, reduced severity of infections) and its efficacy is not adversely affected.

A total of 110 patients will be enrolled in the study. To participate, patients must have multiple myeloma that has progressed despite at least two previous courses of treatment (which may include lenalidomide and bortezomib). Treatment with pomalidomide will continue until there is a demonstrable loss of effect or until unacceptable side effects occur.

If pomalidomide should prove to be equally effective and similarly or even better tolerated when taken every second day, this would represent a helpful new finding for affected patients and the doctors treating them.

All trials